Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor
JNJ-64619178 for Cancer
This trial is testing a new cancer drug to see what doses are tolerated by patients with different types of cancer, including lymphoma and solid tumors. The goal is to also find out what doses of the drug might be effective in treating these cancers.
Radioactive Agent
Iobenguane (131-I) + Vorinostat for Neuroblastoma
This trial tests a combination of a radioactive drug and a cancer-fighting pill in patients with a specific type of neuroblastoma that hasn't responded well to other treatments. The radioactive drug kills cancer cells, and the pill makes them more vulnerable to the drug.
JAK Inhibitor
MMB for Myelofibrosis
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Popular Filters
Trials for Tumors Patients
Monoclonal Antibodies
TSR-022 for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Trials for Adenocarcinoma Patients
OC-001 for Advanced Cancers
This trial is testing a new treatment called OC-001, both by itself and with other drugs that help the immune system fight cancer. It aims to help patients with various types of cancer by making their immune system better at attacking cancer cells.
CAR T-cell Therapy
P-PSMA-101 CAR-T Cells for Prostate Cancer
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Small Molecule Inhibitor
BLU-451 for Lung Cancer
This trial is testing a new drug called BLU-451, alone and with chemotherapy, in patients with advanced cancers that have specific EGFR mutations. The drug works by blocking signals that make cancer cells grow.
Behavioral Intervention
Virtual Group-Based Physical Activity for Cancer Survivors
This trial will test whether group-based physical activity, delivered virtually, is feasible for AYA cancer survivors who have completed treatment. 20 participants will be enrolled for 3 months.
Trials for Metastatic Patients
Monoclonal Antibodies
TSR-022 for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Monoclonal Antibodies
MK-4830 + Pembrolizumab for Cancer
This trial is testing a new drug called MK-4830 alone and with other cancer treatments to see if it is safe and effective. It focuses on cancer patients, including those in China. The treatments work by helping the immune system fight cancer and killing cancer cells.
MDM2 Inhibitor
BI 907828 for Advanced Cancer
This trial is testing a new cancer drug, BI 907828, to see if it's effective and safe. Participants will take BI 907828 either once every three weeks or twice every four weeks, depending on how well they tolerate the drug. The goal is to see if BI 907828 causes tumors to shrink.
Trials for EGFR Positive Patients
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Immunotherapy
MK-0482 + Pembrolizumab for Advanced Cancer
This trial tests a new drug, MK-0482, alone and with pembrolizumab, in patients with advanced cancers who have no other treatment options. MK-0482's safety and effectiveness are being evaluated, while pembrolizumab helps the immune system fight cancer. Pembrolizumab has been widely studied and used in various cancers, showing effectiveness and safety in combination with other treatments.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
Small Molecule Inhibitor
BLU-451 for Lung Cancer
This trial is testing a new drug called BLU-451, alone and with chemotherapy, in patients with advanced cancers that have specific EGFR mutations. The drug works by blocking signals that make cancer cells grow.
Chemotherapy
EMB-01 for Gastrointestinal Cancer
This trial is testing a new drug called EMB-01 for patients with advanced digestive system cancers who haven't responded to other treatments. The drug works by targeting specific genetic changes in the cancer cells to stop their growth.
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
Phase 3 Trials
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Trials With No Placebo
Monoclonal Antibodies
TSR-022 for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
View More Related Trials
Frequently Asked Questions
Introduction to cancer
What are the top hospitals conducting cancer research?
When it comes to groundbreaking cancer research and clinical trials, several esteemed hospitals are at the forefront of innovation. One standout institution is Memorial Sloan Kettering Cancer Center in New york City. With an impressive 11 active cancer trials and a remarkable history of 260 completed trials since its first recorded trial in 1977, this center has been leading the charge against cancer for decades. In Boston, Massachusetts General Hospital is making significant contributions as well, currently conducting eight active cancer trials while having conducted an impressive total of 176 trials throughout its history since their first recorded trial in 1999.
One prominent facility that cannot be overlooked is The University of Texas MD Anderson Cancer Center located in Houston. This renowned center currently has eight active cancer trials underway and has accomplished an admirable tally of 88 previously conducted studies since initiating their inaugural trial in 2006. Additionally, GSK Investigational Site - Dallas also plays a vital role with its eight ongoing clinical tests for cancer treatment while holding a lesser but still important record with sixteen previous investigations dating back to their pioneering investigation on such cases starting only from2008
Lastly adding itself into this list we have GSK Investigational Site -Toronto where they too have same number(8)of ongoing clinical endeavors regarding potential solutions to combatting debilitating disease; they hold twenty-five prior experiments under their belt which began relatively recently just seven years ago during2014.
These top hospitals represent pillars of hope for patients affected by various forms of cancer across the country and beyond. Their unwavering dedication towards understanding this complex disease brings us one step closer to finding more effective treatments and ultimately achieving breakthroughs that will transform lives worldwide
Which are the best cities for cancer clinical trials?
Houston, Texas; New york, New York; Boston, Massachusetts; Nashville, Tennessee; and Toronto, Ontario emerge as the top cities for cancer clinical trials. Houston takes the lead with 50 active trials investigating treatments like SAR443216-Dose Expansion for metastatic gastric cancers with low HER2 expression and Metformin. Meanwhile, New York follows closely behind with 47 ongoing studies exploring novel approaches such as JAKi Naïve Combination Arm and Gene-modified T cell therapy. Similarly, Boston showcases its research prowess through 33 active trials focusing on advancements like P-PSMA-101 CAR-T cells. Additionally, Nashville hosts 27 clinical trials studying therapies like Cetuximab and CYNK-001 while Toronto contributes significantly to the field with its involvement in 25 active trials assessing agents such as CC-95251 and Ipilimumab. These cities serve as hubs of cutting-edge research that offer hope to cancer patients seeking innovative treatment options.
Which are the top treatments for cancer being explored in clinical trials?
Cutting-edge clinical trials are currently exploring a range of top treatments for cancer. Gemcitabine, known for its effectiveness, is being tested in two active trials and has an impressive track record with 81 all-time cancer trials since its first listing in 2001. Another promising candidate is EMB-01, which has shown potential in two ongoing trials and was introduced to the medical community in 2018 alongside BI 907828. Equally noteworthy is ATLCAR.CD30 cells, making waves since its debut on the scene in 2016 with two active and two all-time cancer trials. These innovative therapies offer hope as researchers continue their quest to conquer this complex disease.
What are the most recent clinical trials for cancer?
Exciting progress is being made in the field of cancer research with recent clinical trials offering hope for improved treatments. These include a Phase 1 trial exploring Part B Expansion, which became available on 8/10/2023. Additionally, a Phase 2 trial investigating Arm 1 and its potential benefits for cancer patients was released on 8/2/2023. Another noteworthy study is the Phase 2 Expansion Triplet combination that became available on 7/28/2023, showing promising outcomes in treating cancer. Moreover, VIP236 has shown promise as a potential treatment option in the Dose Escalation phase of its Phase 1 trial starting from January earlier this year. Lastly, there is an ongoing advanced solid tumors study encompassing both Phases 1 and 2 since January to explore novel therapies for these types of cancers. With continued dedication to advancing our understanding and treatment options, we are optimistic about improving outcomes for individuals affected by cancer.
What cancer clinical trials were recently completed?
Numerous innovative clinical trials targeting various types of cancer have recently concluded, signifying significant progress in the field. Among these groundbreaking studies, noteworthy completed trials include pegsitacianine by OncoNano Medicine, Inc., 64Cu-SAR-bisPSMA by Clarity Pharmaceuticals Ltd., ADG116 by Adagene Inc., Pembrolizumab by HiberCell, Inc., Capivasertib by AstraZeneca, and MRTX849 by Mirati Therapeutics Inc. These recent advancements demonstrate the commitment of researchers to finding effective treatments for cancer and offer hope for patients across the globe.